The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Efficacy of Extended-Release Venlafaxine in Nondepressed Outpatients With Generalized Anxiety Disorder
Abstract
OBJECTIVE: This study evaluated the efficacy and safety of fixed doses of once-daily extended-release (XR) venlafaxine in outpatients with generalized anxiety disorder without concomitant major depressive disorder. METHOD: Adult outpatients with generalized anxiety disorder but not major depressive disorder with total scores of 18 or higher on the Hamilton Rating Scale for Anxiety and scores of 2 or higher on its anxious mood and tension factors were eligible. Patients were randomly assigned to receive placebo or venlafaxine XR (75, 150, or 225 mg/day) for 8 weeks. Primary efficacy variables were final total and psychic anxiety factor scores on the Hamilton anxiety scale and final severity and global improvement item scores on the Clinical Global Impression (CGI) scale. RESULTS: Of the 377 patients entering the study, 370 were included in a safety analysis and 349 in an efficacy analysis. Adjusted mean scores at 8 weeks (last-observation-carried-forward analysis) were significantly lower for one or more of the venlafaxine XR groups in four of four primary and three of four secondary outcome measures than for the placebo group. These included a change of 1.7 (versus 1.3) from baseline on CGI severity item scores and a final score of 2.2 (versus 2.6) on the CGI global improvement item. All doses of venlafaxine XR were well tolerated. CONCLUSIONS: Venlafaxine XR is an effective and well-tolerated option for the short-term treatment of generalized anxiety disorder in outpatients without major depressive disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
DSM-III-R Generalized Anxiety Disorder in the National Comorbidity Survey
Wittchen, H.-U. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950050015002 · Cited by 967
Rickels, K. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820230054005 · Cited by 412
Self-citationRASKIN, A., SCHULTERBRANDT, J., REATIG, N., & McKEON, J. J. (1969) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-196901000-00010 · Cited by 373
Kahn, R. J. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800010081010 · Cited by 278
Phenomenology and Course of Generalised Anxiety Disorder
Yonkers, K. A., Warshaw, M. G., Massion, A. O., & Keller, M. B. (1996) · British Journal of Psychiatry · doi:10.1192/bjp.168.3.308 · Cited by 242 · cited 2×
“lengths of 20 years have been reported [3, 4]), and has a low”
BackgroundPsychiatric comorbidity in patients with generalized anxiety disorder
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.8.1216 · Cited by 200
Paroxetine efficacy in the treatment of generalized anxiety disorder
Rocca, P., Fonzo, V., Scotta, M., Zanalda, E., & Ravizza, L. (1997) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1997.tb09660.x · Cited by 194
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Generalized anxiety disorder: prevalence, burden, and cost to society
Wittchen, H.-U. (2002) · Depression and Anxiety · doi:10.1002/da.10065 · Cited by 733
“…have also demonstrated that the SNRI, venlafaxine extended release (XR) (which is also licensed for GAD) are effective in both the short- and long-term treatment of GAD [Allgulander et al., 2001; Davidson et al., 1999; Gelenberg et al., 2000; Rickels et al., 2000; Silverstone and Salinas, 2001].”
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Bandelow, B., Bond, A., Davidson, J. R. T., den Boer, J. A., Fineberg, N. A., Knapp, M., Scott, J., et al. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105059253 · Cited by 617
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Attention modification program in individuals with generalized anxiety disorder
Amir, N., Beard, C., Burns, M., & Bomyea, J. (2009) · Journal of Abnormal Psychology · doi:10.1037/a0012589 · Cited by 539
Stahl, S. M., Grady, M. M., Moret, C., & Briley, M. (2005) · CNS Spectrums · doi:10.1017/s1092852900019726 · Cited by 458
Rynn, M. A., Siqueland, L., & Rickels, K. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.12.2008 · Cited by 321
Self-citationGelenberg, A. J., Lydiard, R. B., Rudolph, R. L., Aguiar, L., Haskins, J. T., & Salinas, E. (2000) · JAMA · doi:10.1001/jama.283.23.3082 · Cited by 296
Self-citationHartford, J., Kornstein, S., Liebowitz, M., Pigott, T., Russell, J., Detke, M., Walker, D., Ball, S., Dunayevich, E., Dinkel, J., et al. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32807fb1b2 · Cited by 286
Feltner, D. E., Crockatt, J. G., Dubovsky, S. J., Cohn, C. K., Shrivastava, R. K., Targum, S. D., Liu-Dumaw, M., Carter, C. M., & Pande, A. C. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000084032.22282.ff · Cited by 260
Comorbidities in Chronic Neuropathic Pain
Nicholson, B., & Verma, S. (2004) · Pain Medicine · doi:10.1111/j.1526-4637.2004.04019.x · Cited by 255
Andrews, G., Bell, C., Boyce, P., Gale, C., Lampe, L., Marwat, O., Rapee, R., & Wilkins, G. (2018) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867418799453 · Cited by 243
Strawn, J. R., Geracioti, L., Rajdev, N., Clemenza, K., & Levine, A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1491966 · Cited by 214
Davidson, J., Rothbaum, B. O., Tucker, P., Asnis, G., Benattia, I., & Musgnung, J. J. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000222514.71390.c1 · Cited by 157
Carl, E., Witcraft, S. M., Kauffman, B. Y., Gillespie, E. M., Becker, E. S., Cuijpers, P., Van Ameringen, M., Smits, J. A. J., & Powers, M. B. (2020) · Cognitive Behaviour Therapy · doi:10.1080/16506073.2018.1560358 · Cited by 151
Anxiety disorders: a comprehensive review of pharmacotherapies
Hoffman, E. J., & Mathew, S. J. (2008) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20041 · Cited by 149
Efficacy of Cognitive Behaviour Therapy in Generalized Anxiety Disorders
Linden, M., Zubraegel, D., Baer, T., Franke, U., & Schlattmann, P. (2005) · Psychotherapy and Psychosomatics · doi:10.1159/000082025 · Cited by 142
Systematic review and meta-analysis: dose-response curve of SSRIs and SNRIs in anxiety disorders
Jakubovski, E., Johnson, J. A., Nasir, M., Müller-Vahl, K., & Bloch, M. H. (2019) · Depression and Anxiety · doi:10.1002/da.22854 · Cited by 131
Gomez, A. F., Barthel, A. L., & Hofmann, S. G. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1472767 · Cited by 125
Roest, A. M., de Jonge, P., Williams, C. D., de Vries, Y. A., Schoevers, R. A., & Turner, E. H. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.15 · Cited by 101
Anxiety and Depression: Optimizing Treatments
Ballenger, J. C. (2000) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v02n0301 · Cited by 83
Rickels, K., Etemad, B., Khalid-Khan, S., Lohoff, F. W., Rynn, M. A., & Gallop, R. J. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.170 · Cited by 63
Self-citationDefining Response and Remission in Anxiety Disorders: Toward an Integrated Approach
Bandelow, B. (2006) · CNS Spectrums · doi:10.1017/s1092852900025815 · Cited by 52
Meta-analysis: Risk of dry mouth with second generation antidepressants
Cappetta, K., Beyer, C., Johnson, J. A., & Bloch, M. H. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.12.012 · Cited by 49
Benzodiazepines in anxiety disorders: Reassessment of usefulness and safety
Rickels, K., & Moeller, H. J. (2019) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2018.1500031 · Cited by 30
Self-citationHoge, E. A., Oppenheimer, J. E., & Simon, N. M. (2004) · Focus · doi:10.1176/foc.2.3.346 · Cited by 19
Antidepressants versus placebo for generalised anxiety disorder (GAD)
Kopcalic, K., Arcaro, J., Pinto, A., Ali, S., Barbui, C., Curatoli, C., Martin, J., & Guaiana, G. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012942.pub2 · Cited by 16
Metadata
- Authors
- Rickels, K., Pollack, M. H., Sheehan, D. V., & Haskins, J. T.
- Venue
- American Journal of Psychiatry
- Published
- 2000-06-01
- Volume
- 157
- Issue
- 6
- Pages
- 968-974
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2084977025
- Cited by
- 252
- References
- 24
- FWCI
- 30.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.